HomeAI · summaries
Storia in 3 fonti
Novartis gains full FDA nod for Fabhalta in kidney disorder IgAN
With two approved medicines to treat primary immunoglobulin A nephropathy (IgAN) and a third therapy in phase 3 testing, Novartis is on its way to cornering the market for the indication. | The FDA has converted its accelerated approval for Novartis' Fabhalta into a full blessing to treat patients with immunoglobulin A nephropathy (IgAN). The drug is endorsed to slow kidney function decline in adults at risk of disease progression.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Fabhalta gains full FDA approval for proteinuria reduction in IgA nephropathy
The FDA granted full approval to iptacopan to slow kidney function decline in adults with primary immunoglobulin A nephropathy at risk for disease progression, according to a…
- ·
fiercepharma.com
Novartis gains full FDA nod for Fabhalta in kidney disorder IgAN
With two approved medicines to treat primary immunoglobulin A nephropathy (IgAN) and a third therapy in phase 3 testing, Novartis is on its way to cornering the market for the…
- ·
benzinga.com
This Novartis Drug Could Help Delay Dialysis—FDA Grants Full Approval - Novartis (NYSE:NVS)
Novartis wins traditional FDA approval for Fabhalta, a first-in-class oral treatment slowing kidney decline in adult IgAN.